Table 4 Comparison of S100A8/A9 concentrations between patients with individual NPSLE-manifestations and non-NPSLE-patients according to the NPSLE ACR model
Patient group (ACR model) | Serum S100A8/A9, ng/ml, median (range) | CSF S100A8/A9, pg/ml, median (range) |
|---|---|---|
Non-NPSLE patients (reference group), | 920 (50–3500) | 416 (< 35–2045) |
n (%) | 28 (39%) | 11 (34%) |
Cognitive dysfunction, | 1380 (260–3540) | 319 (< 35–1703) |
n (%) | 26 (36%) | 15 (47%) |
p value | 0.013 | 0.36 |
Headache, | 1300 (140–2860) | 252 (< 35–854) |
n (%) | 22 (31%) | 9 (28%) |
p value | 0.058 | 0.37 |
Depression, | 1460 (140–2790) | 177 (< 35–526) |
n (%) | 13 (18%) | 6 (19%) |
p value | 0.007 | 0.2 |
Anxiety, | 1220 (260–2790) | 143 (< 35–692) |
n (%) | 12 (17%) | 6 (19%) |
p-value | 0.14 | 0.17 |
Autonomous neuropathy, | 1280 (280–2440) | 304 (< 35–854) |
n (%) | 10 (14%) | 6 (19%) |
p value | 0.14 | 0.61 |
Cranial neuropathy, | 1460 (280–2190) | 756 (692–854) |
n (%) | 7 (10%) | 3 (9%) |
p value | 0.087 | - |
Cerebrovascular disease, | 1730 (740–2860) | 692 |
n (%) | 5 (7%) | 1 (3%) |
p value | 0.1 | - |